Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/Ib Trial of Elimusertib in Combination With FOLFIRI in GI Malignancies
NCT04535401Phase 1Active, not recruiting
- Sponsor
- National Cancer Institute
- Start
- Aug 2021
- Primary completion
- Feb 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of elimusertib in gastrointestinal cancer, colorectal cancer (CRC), gastric cancer (GC) and 1 more, sponsored by National Cancer Institute. Primary endpoints: Maximum Tolerated Dose up to 28 days and Dose-Limiting Toxicities up to 28 days. Started Aug 2021; status: active, not recruiting.
02
Drugs
elimusertib
03
Conditions
gastrointestinal cancercolorectal cancer (CRC)gastric cancer (GC)gastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT04535401.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04535401.